WahanaRiau.com - Biognosys ag

Berita Politik Peristiwa Ekonomi Otomotif Olahraga Teknologi Gaya Hidup Travel Video Media OutReach Globenewswire Advertorial Pilihan Editor Terpopuler Indeks

Biognosys ag

Index

Globenewswire

Biognosys Meluncurkan Spectronaut 19 dan Mempresentasikan Kemajuan dengan Platform Risetnya di Konferensi Tahunan ASMS 2024

Selasa, 04 Juni 2024 - 05:15:13 Wib

Globenewswire

Biognosys Meluncurkan Terobosan Teknologi Pengayaan Plasma P2 untuk Proteomik Plasma yang tidak Bias dan dalam di ASMS 2024

Senin, 03 Juni 2024 - 05:12:28 Wib

Globenewswire

Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference

Jumat, 31 Mei 2024 - 04:54:10 Wib

Globenewswire

Biognosys Launches Groundbreaking P2 Plasma Enrichment Technology for Unbiased, Deep Plasma Proteomics at ASMS 2024

Jumat, 31 Mei 2024 - 04:52:28 Wib

Globenewswire

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Jumat, 05 April 2024 - 22:35:13 Wib

Biognosys ag

Biognosys Meluncurkan Spectronaut 19 dan Mempresentasikan Kemajuan dengan Platform Risetnya di Konferensi Tahunan ASMS 2024

Biognosys Meluncurkan Terobosan Teknologi Pengayaan Plasma P2 untuk Proteomik Plasma yang tidak Bias dan dalam di ASMS 2024

Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference

Biognosys Launches Groundbreaking P2 Plasma Enrichment Technology for Unbiased, Deep Plasma Proteomics at ASMS 2024

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Terpopuler

Toluna Brings AI-Native Research to Every Team With Toluna Bina
Dibaca: 116 Kali

From Movie Sets to Experimental Games: Meet the Craftspeople Shaping Genshin Impact's Miliastra Wonderland
Dibaca: 106 Kali

Templafy Report Finds 95% of Knowledge Workers Edit AI-Generated Documents Before They’re Business-Ready
Dibaca: 114 Kali

New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Journeys
Dibaca: 108 Kali

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Dibaca: 103 Kali

Terkini

YYForce Deploys Hospitality Service Robot at Aloft by Marriott Langkawi Pantai Tengah in Malaysia

Toluna Brings AI-Native Research to Every Team With Toluna Bina

From Movie Sets to Experimental Games: Meet the Craftspeople Shaping Genshin Impact's Miliastra Wonderland

Laporan Templafy Mengungkap 95% Pekerja Intelektual Mengedit Dokumen Buatan AI Sebelum Siap Digunakan untuk Kebutuhan Bisnis

Streamex CEO Henry McPhie to Embark on Asia Tour with Events in Singapore and Hong Kong

Biognosys ag

Terpopuler

Toluna Brings AI-Native Research to Every Team With Toluna Bina Dibaca: 116 Kali

From Movie Sets to Experimental Games: Meet the Craftspeople Shaping Genshin Impact's Miliastra Wonderland Dibaca: 106 Kali

Templafy Report Finds 95% of Knowledge Workers Edit AI-Generated Documents Before They’re Business-Ready Dibaca: 114 Kali

New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Journeys Dibaca: 108 Kali

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes Dibaca: 103 Kali

Terkini

Toluna Brings AI-Native Research to Every Team With Toluna Bina
Dibaca: 116 Kali

From Movie Sets to Experimental Games: Meet the Craftspeople Shaping Genshin Impact's Miliastra Wonderland
Dibaca: 106 Kali

Templafy Report Finds 95% of Knowledge Workers Edit AI-Generated Documents Before They’re Business-Ready
Dibaca: 114 Kali

New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Journeys
Dibaca: 108 Kali

Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Dibaca: 103 Kali